Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2015

01-10-2015 | Original Article

Effect of hematuria on the outcome of IgA nephropathy with mild proteinuria

Authors: Kayu Tanaka, Takahito Moriyama, Chihiro Iwasaki, Takashi Takei, Kosaku Nitta

Published in: Clinical and Experimental Nephrology | Issue 5/2015

Login to get access

Abstract

Background

The effects of hematuria on the outcome of IgA nephropathy (IgAN) remain unknown and treatment of IgAN with severe hematuria is controversial.

Methods

Eighty-eight IgAN patients with proteinuria <0.5 g/day and who had not received corticosteroids, immunosuppressive agents, or undergone a tonsillectomy were divided into two groups: (1) patients with low (<20/high-power field [HPF]) urinary red blood cell (U-RBC) counts (L-RBC group, n = 48); and (2) patients with high (≥20/HPF) U-RBC counts (H-RBC group, n = 40). Clinical and histological findings, renal survival rate and risk factors for progression were analyzed.

Results

The male ratio and blood pressure were significantly higher in the L-RBC group. Median proteinuria, mean estimated glomerular filtration rate and histological findings according to Oxford classifications were similar. During the 5 years after renal biopsy, the median amount of proteinuria remained at <0.5 g/day or g/g creatinine in both groups, and the median U-RBC decreased to <10/HPF in both groups without any intensive therapy. The 15-year renal survival rate, estimated using the Kaplan–Meier method, was 100 % in the H-RBC group, but decreased to 83.4 % in the L-RBC group, although it was not significant. The treatment of inhibitors of renin–angiotensin system (RAS inhibitors) decreased the risk for progression by Cox regression analysis (hazard ratio: 0.14, p = 0.027).

Conclusion

Severe hematuria at the time of biopsy naturally improved without any intensive therapy, and there were no negative effects of hematuria on the outcome of IgAN with mild proteinuria. Its prognosis was relatively good, and the treatment of RAS inhibitors might prevent from progression.
Literature
1.
go back to reference Moriyama T, Tanaka K, Iwasaki C, Oshima Y, Ochi A, Kataoka H, Itabashi M, Takei T, Uchida K, Nitta K. Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS One. 2014;9:e91756.PubMedCentralCrossRefPubMed Moriyama T, Tanaka K, Iwasaki C, Oshima Y, Ochi A, Kataoka H, Itabashi M, Takei T, Uchida K, Nitta K. Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS One. 2014;9:e91756.PubMedCentralCrossRefPubMed
2.
go back to reference Alamartine E, Sabatier JC, Guerin C, Berliet JM, Berthoux F. Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analysis. Am J Kidney Dis. 1991;18:12–9.CrossRefPubMed Alamartine E, Sabatier JC, Guerin C, Berliet JM, Berthoux F. Prognostic factors in mesangial IgA glomerulonephritis: an extensive study with univariate and multivariate analysis. Am J Kidney Dis. 1991;18:12–9.CrossRefPubMed
3.
go back to reference Koyama A, Igarashi M, Kobayashi M. Coworkers of the research group on progressive renal disease: natural history and risk factors for immunoglobulin A nephropathy in Japan. Am J Kidney Dis. 1997;29:526–32.CrossRefPubMed Koyama A, Igarashi M, Kobayashi M. Coworkers of the research group on progressive renal disease: natural history and risk factors for immunoglobulin A nephropathy in Japan. Am J Kidney Dis. 1997;29:526–32.CrossRefPubMed
4.
go back to reference Le W, Liang S, Hu Y, Deng K, Bao H, Zeng C, Liu Z. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012;27:1479–85.CrossRefPubMed Le W, Liang S, Hu Y, Deng K, Bao H, Zeng C, Liu Z. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012;27:1479–85.CrossRefPubMed
5.
go back to reference Lee H, Kim DK, Oh KH, Joo KW, Kim YS, Chae DW, Kim S, Chin HJ. Mortality of IgA nephropathy patients: a single center experience over 30 years. PLoS One. 2012;7:e51225.PubMedCentralCrossRefPubMed Lee H, Kim DK, Oh KH, Joo KW, Kim YS, Chae DW, Kim S, Chin HJ. Mortality of IgA nephropathy patients: a single center experience over 30 years. PLoS One. 2012;7:e51225.PubMedCentralCrossRefPubMed
6.
go back to reference Jalalah SM, Alzahrani IH, Furness PN. Glomerular changes in microscopic hematuria, studied by quantitative immunoelecton microscopy and in situ zymography. Nephrol Dial Transplant. 2002;17:2586–93.CrossRef Jalalah SM, Alzahrani IH, Furness PN. Glomerular changes in microscopic hematuria, studied by quantitative immunoelecton microscopy and in situ zymography. Nephrol Dial Transplant. 2002;17:2586–93.CrossRef
7.
go back to reference Rauta V, Finne P, Fagerudd J, Rosenlof K, Tornroth T, Gronhagen-Riska C. Factors associated with progression IgA nephropathy are related to renal function-a model for estimating risk of progression in mild disease. Clin Nephrol. 2002;58:85–94.CrossRefPubMed Rauta V, Finne P, Fagerudd J, Rosenlof K, Tornroth T, Gronhagen-Riska C. Factors associated with progression IgA nephropathy are related to renal function-a model for estimating risk of progression in mild disease. Clin Nephrol. 2002;58:85–94.CrossRefPubMed
8.
go back to reference Suzuki Y, Matsuzaki K, Suzuki H, Sakamoto N, Joh K, Kawamura T, Tomino Y, Matsuo S. Proposal of remission criteria for IgA nephropathy. Clin Exp Nephrol. 2014;18:481–6.CrossRefPubMed Suzuki Y, Matsuzaki K, Suzuki H, Sakamoto N, Joh K, Kawamura T, Tomino Y, Matsuo S. Proposal of remission criteria for IgA nephropathy. Clin Exp Nephrol. 2014;18:481–6.CrossRefPubMed
9.
go back to reference Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D’Agati V, D’Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Leung CB, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76:534–45.CrossRefPubMed Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D’Agati V, D’Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Leung CB, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76:534–45.CrossRefPubMed
10.
go back to reference Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, Cattran DC, Coppo R, D’Agati V, D’Amico G, Emancipator S, Emma F, Feehally J, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford classification of IgA nephropathy: pathology, definitions, correlations, and reproducibility. Kidney Int. 2009;76:546–56.CrossRefPubMed Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, Barratt J, Berthoux F, Bonsib S, Bruijn JA, Cattran DC, Coppo R, D’Agati V, D’Amico G, Emancipator S, Emma F, Feehally J, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford classification of IgA nephropathy: pathology, definitions, correlations, and reproducibility. Kidney Int. 2009;76:546–56.CrossRefPubMed
11.
go back to reference Szeto CC, Lai FM, To KF, Wong TY, Chow KM, Choi PC, Lui SF, Li PK. The natural history of immunoglobulin A nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001;110:434–7.CrossRefPubMed Szeto CC, Lai FM, To KF, Wong TY, Chow KM, Choi PC, Lui SF, Li PK. The natural history of immunoglobulin A nephropathy among patients with hematuria and minimal proteinuria. Am J Med. 2001;110:434–7.CrossRefPubMed
12.
go back to reference Shen P, He L, Li Y, Wang Y, Chan M. Natural history and prognostic factors of IgA nephropathy presented with isolated microscopic hematuria in Chinese patients. Nephron Clin Pract. 2007;106:157–61.CrossRef Shen P, He L, Li Y, Wang Y, Chan M. Natural history and prognostic factors of IgA nephropathy presented with isolated microscopic hematuria in Chinese patients. Nephron Clin Pract. 2007;106:157–61.CrossRef
13.
go back to reference Shen P, He L, Huang D. Clinical course and prognostic factors of clinically early IgA nephropathy. Neth J Med. 2008;66:242–7.PubMed Shen P, He L, Huang D. Clinical course and prognostic factors of clinically early IgA nephropathy. Neth J Med. 2008;66:242–7.PubMed
14.
go back to reference Harmankaya Ö, Öztürk Y, Baştürk T, Öbek A, Kılıçarslan I. Efficacy of immunsuppressivetherapy in IgA nephropathy presenting with isolated hematuria. Int Urol Nephrol. 2002;33:167–71.CrossRefPubMed Harmankaya Ö, Öztürk Y, Baştürk T, Öbek A, Kılıçarslan I. Efficacy of immunsuppressivetherapy in IgA nephropathy presenting with isolated hematuria. Int Urol Nephrol. 2002;33:167–71.CrossRefPubMed
15.
go back to reference Manno C, Strippoli GFN, D’Alti C, Torres D, Rossini M, Schena FP. A novel simplar histological classification for renal survival in IgA nephropathy: a retrospective study. Am J Kidney Dis. 2007;49:763–75.CrossRefPubMed Manno C, Strippoli GFN, D’Alti C, Torres D, Rossini M, Schena FP. A novel simplar histological classification for renal survival in IgA nephropathy: a retrospective study. Am J Kidney Dis. 2007;49:763–75.CrossRefPubMed
16.
go back to reference Gutiérrez E, Zamora I, Ballarín JA, Arce Y, Jiménez S, Quereda C, Olea T, Martínez-Ara J, Segarra A, Bernis C, García A, Goicoechea M, García de Vinuesa S, Rojas-Rivera J, Praga M, Grupo de Estudio de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN). Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol. 2012;23:1753–60.PubMedCentralCrossRefPubMed Gutiérrez E, Zamora I, Ballarín JA, Arce Y, Jiménez S, Quereda C, Olea T, Martínez-Ara J, Segarra A, Bernis C, García A, Goicoechea M, García de Vinuesa S, Rojas-Rivera J, Praga M, Grupo de Estudio de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN). Long-term outcomes of IgA nephropathy presenting with minimal or no proteinuria. J Am Soc Nephrol. 2012;23:1753–60.PubMedCentralCrossRefPubMed
17.
go back to reference Kim BS, Kim YK, Shin YS, Kim YO, Song HC, Kim YS, Choi EJ. Natural history and renal pathology in patients with isolated microscopic hematuria. Korean J Intern Med. 2009;24:356–61.PubMedCentralCrossRefPubMed Kim BS, Kim YK, Shin YS, Kim YO, Song HC, Kim YS, Choi EJ. Natural history and renal pathology in patients with isolated microscopic hematuria. Korean J Intern Med. 2009;24:356–61.PubMedCentralCrossRefPubMed
Metadata
Title
Effect of hematuria on the outcome of IgA nephropathy with mild proteinuria
Authors
Kayu Tanaka
Takahito Moriyama
Chihiro Iwasaki
Takashi Takei
Kosaku Nitta
Publication date
01-10-2015
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2015
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-014-1068-9

Other articles of this Issue 5/2015

Clinical and Experimental Nephrology 5/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.